UDP disodium saltEndogenous ligand; competitive antagonist at P2Y14 receptors CAS# 27821-45-0 |
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 27821-45-0 | SDF | Download SDF |
PubChem ID | 3084485 | Appearance | Powder |
Formula | C9H12N2Na2O12P2 | M.Wt | 448.12 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | disodium;[[(2R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate | ||
SMILES | C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)([O-])[O-])O)O.[Na+].[Na+] | ||
Standard InChIKey | ZQKVPFKBNNAXCE-HVQNCJTOSA-L | ||
Standard InChI | InChI=1S/C9H14N2O12P2.2Na/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18;;/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,10,12,15)(H2,16,17,18);;/q;2*+1/p-2/t4-,6?,7?,8-;;/m1../s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Endogenous P2Y receptor agonist which preferentially activates P2Y6. Shown to be a competitive antagonist at P2Y14 receptors. |
UDP disodium salt Dilution Calculator
UDP disodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2315 mL | 11.1577 mL | 22.3155 mL | 44.6309 mL | 55.7886 mL |
5 mM | 0.4463 mL | 2.2315 mL | 4.4631 mL | 8.9262 mL | 11.1577 mL |
10 mM | 0.2232 mL | 1.1158 mL | 2.2315 mL | 4.4631 mL | 5.5789 mL |
50 mM | 0.0446 mL | 0.2232 mL | 0.4463 mL | 0.8926 mL | 1.1158 mL |
100 mM | 0.0223 mL | 0.1116 mL | 0.2232 mL | 0.4463 mL | 0.5579 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Loroquine
Catalog No.:BCN2008
CAS No.:27792-82-1
- Uncarinic acid E
Catalog No.:BCN6774
CAS No.:277751-61-8
- 9-Angeloylretronecine N-oxide
Catalog No.:BCN2037
CAS No.:27773-86-0
- Ervamycine
Catalog No.:BCN5172
CAS No.:27773-39-3
- 5-Hydroxy-1-methoxyxanthone
Catalog No.:BCN6575
CAS No.:27770-13-4
- Pahutoxin
Catalog No.:BCN1811
CAS No.:27742-14-9
- Geniposidic acid
Catalog No.:BCN5171
CAS No.:27741-01-1
- Erysotrine
Catalog No.:BCN5170
CAS No.:27740-43-8
- Scutellarin
Catalog No.:BCN5902
CAS No.:27740-01-8
- 2,4-Bis(α,α-dimethylbenzyl)phenol
Catalog No.:BCC8498
CAS No.:2772-45-4
- 7-Megastigmene-3,5,6,9-tetraol
Catalog No.:BCN5168
CAS No.:276870-26-9
- Cryptomoscatone D2
Catalog No.:BCN7203
CAS No.:276856-55-4
- Sunset yellow
Catalog No.:BCN2222
CAS No.:2783-94-0
- Serratenediol diacetate
Catalog No.:BCN5173
CAS No.:27832-84-4
- Loxapine Succinate
Catalog No.:BCC4674
CAS No.:27833-64-3
- Macrophylline
Catalog No.:BCN1987
CAS No.:27841-97-0
- Nicergoline
Catalog No.:BCC5214
CAS No.:27848-84-6
- Lamiide
Catalog No.:BCN4656
CAS No.:27856-54-8
- NH125
Catalog No.:BCC4001
CAS No.:278603-08-0
- Croceic acid
Catalog No.:BCN2372
CAS No.:27876-94-4
- GW4064
Catalog No.:BCC4500
CAS No.:278779-30-9
- Bis(4-bromophenyl)acetylene
Catalog No.:BCC8882
CAS No.:2789-89-1
- H-Lys(Z)-OMe.HCl
Catalog No.:BCC2988
CAS No.:27894-50-4
- H-Glu(OBzl)-OBzl.TosOH
Catalog No.:BCC2928
CAS No.:2791-84-6
UDP is a competitive antagonist at the human P2Y14 receptor.[Pubmed:18252808]
J Pharmacol Exp Ther. 2008 May;325(2):588-94.
G protein-coupled P2Y receptors (P2Y-R) are activated by adenine and uracil nucleotides. The P2Y(14) receptor (P2Y(14)-R) is activated by at least four naturally occurring UDP sugars, with UDP-glucose (UDP-Glc) being the most potent agonist. With the goal of identifying a competitive antagonist for the P2Y(14)-R, UDP was examined for antagonist activity in COS-7 cells transiently expressing the human P2Y(14)-R and a chimeric Galpha protein that couples Gi-coupled receptors to stimulation of phosphoinositide hydrolysis. UDP antagonized the agonist action of UDP-Glc, and Schild analysis confirmed that the antagonism was competitive (pK(B) = 7.28). Uridine 5'-O-thiodiphosphate also antagonized the human P2Y(14)-R (hP2Y(14)-R) with an apparent affinity similar to that of UDP. In contrast, no antagonist activity was observed with ADP, CDP, or GDP, and other uracil analogs also failed to exhibit antagonist activity. The antagonist activity of UDP was not observed at other hP2Y-R. In contrast to its antagonist action at the hP2Y(14)-R, UDP was a potent agonist (EC(50) = 0.35 muM) at the rat P2Y(14)-R. These results identify the first competitive antagonist of the P2Y(14)-R and demonstrate pharmacological differences between receptor orthologs.